Because Ras might not be the single driving force in many cancers where FTIs were tested, additional therapies in combination with FTIs might offer a more advantageous outcome, such as taxanes or signal transduction inhibitors of the PI3K-AKT pathway. This evidence concerns the gene AKT1 and cancer.